International Test Laboratories of Newark, NJ has found that the chemical grafting process known as Formula 51 to have met the minimal time effectiveness requirement with anticipation of long range success of up to 10 years, when applied to a variety of substrate surfaces.
Formula 51 now known as SurfaceShield, which was developed by Polymer Research Corporation of America, when combined with its chemical grafting process and anti-microbiological killing agents is designed to provide a long term killing effectiveness against a wide variety of bacteria, viruses, germs and fungi, including but not limited to, E-Coli, Salmonella, Staphylococcus, Rhinovirus, HIV, Herpes, Hepatitis B, Gonorrhea, and Syphilis. The grafting process allows for SurfaceShield to chemically bond with common substrate surfaces such as glass, wood, tile, plastics, metals, etc. Phase 2 of the testing which will test the actual killing cycle, which is anticipated to be 30 to 90 days or longer after application, is scheduled to begin within the next 10 days.
Cerno Holdings in conjunction with International Test Laboratories is presently researching the addition of another compound to the present disinfectant formulation that will allow SurfaceShield to be a killing agent of the Anthrax Virus in its vegetative or pre-spore state. The results of this research are anticipated within the next 45-60 days.
SurfaceShield is a clear, odorless solution with non-corrosive, non-flammable and non-toxic properties. It will be packaged in commercial bulk quantity and household and personal size sprays. Due to its anticipated long-term effectiveness, the cost to disinfect an area normally requiring daily sanitizing will be reduced appreciably.
Cerno believes SurfaceShield when brought to the market within the next six months will generate significant revenues to the company and its parent, 37Point9.
For additional information relating to SurfaceShield please refer to 37Point9's web site, and view the section under subsidiaries listed as Cerno Holdings.
Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. 37Point9 disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services and changes in our business strategies.